Interfering with cell-survival signalling as a treatment strategy for prostate cancer

BJU International

Volumn 97, Issue 6, 2006, Pages 1149-1153

  Corcoran, Niall M ^a   Costello, Anthony J ^a,b   Hovens, Christopher M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Novartis Australia ^*  (Australia)

Author keywords

Apoptosis; Cell survival; Prostate; Prostatic malignancy; Signalling

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BORTEZOMIB; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIRUBICIN; ERLOTINIB; ESTRAMUSTINE; EVEROLIMUS; GEFITINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OBLIMERSEN; PERIFOSINE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CELL SURVIVAL; CLINICAL TRIAL; DRUG FATALITY; DRUG RESEARCH; HUMAN; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION; STOMACH PERFORATION; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

APOPTOSIS; CELL COMMUNICATION; CELL SURVIVAL; HUMANS; MALE; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

EID: 33745206514     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06198.x     Document Type: Short Survey

References (33)

1. Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005 11: 3854 61
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004 351: 1513 20
3. Tannock IF, de Wit R, Berry WR et al.; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004 351: 1502 12
4. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999 18: 7389 94
5. Gasparian AV, Yao YJ, Kowalczyk D et al. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002 115: 141 51
6. Lessard L, Mes-Masson AM, Lamarre L, Wall L, Lattouf JB, Saad F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int 2003 91: 417 20
7. An J, Fisher M, Rettig MB. VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene 2005 24: 1563 70
8. Price N, Dreicer R. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer 2004 3: 141 3
9. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004 22: 2532 9
10. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001 12: 1273 9
11. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001 28 ( Suppl. 4 8 15
12. Ferrero JM, Foa C, Thezenas S et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology 2004 66: 281 7
13. Gravis G, Bladou F, Salem N et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 2003 98: 1627 34
14. Olapade-Olaopa EO, Moscatello DK, MacKay EH et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000 82: 186 94
15. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 350: 2129 39
16. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 290: 2149 58
17. Cappuzzo F, Gregorc V, Rossi E et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003 21: 2658 63
18. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med 2004 351: 2883
19. Canil CM, Moore MJ, Winquist E et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005 23: 455 60
20. Kulp SK, Yang YT, Hung CC et al. 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004 64: 1444 51
21. Zha S, Gage WR, Sauvageot J et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001 61: 8617 23
22. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 2002 13: 427 34
23. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002 77: 219 25
24. Zhong BK, Hwang S, Cogswell J et al. Second line treatment of hormone resistant prostate cancer. A phase II trial of epirubicin, estramustine phosphate and celecoxib. ASCO Annual Meeting, Florida 2005: A4754
25. Kasimis BJ, Hwang S, Chang VT et al. High dose celecoxib and docetaxel in patients with hormone resistant prostate cancer. results of an ongoing phase II trial. In ASCO Annual Meeting, Florida 2005: A4704
26. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004 351: 1709 11
27. Yang L, Dan HC, Sun M et al. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 2004 64: 4394 9
28. Posadas EM, Gulley J, Arlen PM et al. A phase II study of perifosine in androgen independent prostate cancer. Cancer Biol Ther 2005 4: 1133 7
29. Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001 98: 10314 9
30. Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004 22: 2336 47
31. Atkins MB, Hidalgo M, Stadler WM et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 22: 909 18
32. Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004 10: 594 601
33. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Invest Drugs 2002 3: 295 304